Janssen
Manufacturing · New Jersey, United States · 40,000 Employees
Who is Janssen
Janssen is a pharmaceutical company that focus on areas of medicine where they can make the biggest difference: Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension. Janssen is a subsidiary of Johnson & Johnson and is headquartered in Raritan, New Jersey.Read More
Headquarters:
1125 Trenton-Harbourton Road, Titusville, New Jersey, 08560, United States
Phone Number:
(908) 218-6095
Revenue:
$40 Billion
Janssen's Social Media
Popular Searches:
Janssen Pharmaceuticals Inc
Janssen Products , LP
Janssen CarePath
Janssen Inc.
Janssen Group of Companies
Top Competitors of Janssen
Janssen's Org Chart
Phone
Email
PhoneEmail
Janssen Company Metrics
Revenue
| Quarter | Revenue |
|---|---|
'21 - Q1 | 40700000000 |
'21 - Q2 | 40700000000 |
Acquisitions & Subsidiaries
Dec 17, 2021
bebe
Feb 07, 2019
Desitin
Dec 31, 2017
Exuviance
Sep 11, 2017
Penaten
Jun 23, 2017
Piz Buin
Oct 27, 2016
Medical Enterprises Distribution
See More Acquisitions & Subsidiaries
Janssen's Tech Stack
Janssen News & Media
European Commission Grants Conditional Approval of CARVYKTI® (Ciltacabtagene Autoleucel), Janssen’s First Cell Therapy, for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
BEERSE, Belgium--(BUSINESS WIRE)--The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the European Commission (EC) granted conditional marketing authorisation of CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed and refractory multiple myeloma (RRMM) who have received at least three prior therapies, including an immunomodulatory agent (IMiD), a proteasome inhibitor (PI) and an anti-CD38 antibody, and have demonstrated disea
May 26, 2022
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA® (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
New data show proportions of patients treated with TREMFYA who achieved clinical-biomarker response ranged from 47.5-66.7 percent across dose groups in the Phase 2 GALAXI 1 study Other data presented demonstrate the long-term safety profile of STELARA® (ustekinumab) in bio-naïve and...May 24, 2022
New Data Show TREMFYA® (guselkumab) Binds to Both Inflammatory Cells and Interleukin (IL)-23, Supporting a Hypothesis for a Differentiated Mechanism from Risankizumab
In vitro studies suggest TREMFYA neutralizes IL-23 where it is produced, enhancing the ability of TREMFYA to prevent local activation of cells that drive inflammation TREMFYA is the first fully human IL-23 inhibitor indicated for adults with moderate to severe plaque psoriasis and adults...May 18, 2022Subscribe to "Janssen" News
Frequently Asked Questions regarding Janssen
Where are Janssen’s headquarters?
Janssen’s headquarters are in 1125 Trenton-Harbourton Road, Titusville, New Jersey, 08560, United States
What is Janssen’s phone number?
Janssen’s phone number is (908) 218-6095
What is Janssen’s official website?
Janssen’s official website is www.janssen.com
What is Janssen’s Revenue?
Janssen’s revenue is $40 Billion
What is Janssen’s SIC code?
Janssen’s SIC: 28,283
What is Janssen’s NAICS code?
Janssen’s NAICS: 32541,325
How many employees are working in Janssen?
Janssen has 40,000 employees
What is Janssen’s industry?
Janssen is in the industry of: Manufacturing, Pharmaceuticals
Who are Janssen’s main competitors?
Janssen's main competitors are: Alkermes, Astellas Pharma, AstraZeneca, Amarin Corporation
What companies has Janssen acquired?
Janssen has acquired the companies: bebe, Desitin, Exuviance, Penaten
What is Janssen's tech stack?
The technologies that are used by Janssen are: Replicon, Trend Micro, Dataiku, ARGUS
Test Drive ZoomInfo's Directories
Browse Directories
